MC/CAR (ATCC® CRL-8083™)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte

Organism Homo sapiens, human
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2
Disease plasmacytoma; myeloma
Age 81 years
Gender male
Ethnicity Caucasian
Applications
Although derived from cells taken from a patient with a plasmacytoma, this line has been shown to be an EBV-transformed B lymphoblastoid cell line.
The cells produce, but do not secrete, immunoglobulin.
Can be used as a human fusion line.
Karyotype normal male diploid
Derivation
Although derived from cells taken from a patient with a plasmacytoma, this line has been shown to be an EBV-transformed B lymphoblastoid cell line.
Clinical Data
Although derived from cells taken from a patient with a plasmacytoma, this line has been shown to be an EBV-transformed B lymphoblastoid cell line.
male
Caucasian
81 years
Markers
HLA A1, A33/31, B7, B18, DRw1, DRw2; CD11a +; CD19 +; CD20 + CD28 -; CD38 +
complement (C3b)
Genes Expressed
immunoglobulin,HLA A1, A33/31, B7, B18, DRw1, DRw2; CD11a +; CD19 +; CD20 + CD28 -; CD38 +
Tumorigenic Yes
Comments
Although derived from cells taken from a patient with a plasmacytoma, this line has been shown to be an EBV-transformed B lymphoblastoid cell line.
The cells produce, but do not secrete, immunoglobulin.
No surface immunoglobulin.
8-azaguanine mutants may be cloned out or mutagenized for HAT sensitive cultures.
Can be used as a human fusion line.
Complete Growth Medium Iscove's modified Dulbecco's medium, 80%; fetal bovine serum, 20%
Subculturing
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 X 10 exp5 cells/ml and maintain between 5 X 10 exp5 and 1 X 10 exp6 cells/ml.
Culture Conditions
Temperature: 37.0°C
STR Profile
Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 11,13
D16S539: 11,12
D5S818: 11,14
D7S820: 9,13
THO1: 6,9
TPOX: 8
vWA: 17,18
Isoenzymes
ADA, 1
AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 1
PGM1, 1
PGM3, 1
Isotype IgG1 (cytoplasmic); kappa light chain
Name of Depositor Research Corporation
References

Ritts RE Jr.. Human nonsecretory plasmacytoid cell line. US Patent 4,434,230 dated Feb 28 1984

Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375

Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762

Ritts RE J, et al. Establishment and characterization of a human non-secretory plasmacytoid cell line and its hybridization with human B cells. Int. J. Cancer 31: 133-141, 1983. PubMed: 6600719

Tumors developed within 21 days at 100% frequency (5/5).

Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
MSDS
MSDS
References

Ritts RE Jr.. Human nonsecretory plasmacytoid cell line. US Patent 4,434,230 dated Feb 28 1984

Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375

Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762

Ritts RE J, et al. Establishment and characterization of a human non-secretory plasmacytoid cell line and its hybridization with human B cells. Int. J. Cancer 31: 133-141, 1983. PubMed: 6600719

Tumors developed within 21 days at 100% frequency (5/5).